GlassScriptPhysician profile
Nicole Mcdonald
NPI 1992744080
$5,159.19
in general payments reported to CMS, 2019-2025
34 companies · $91.30 in 2025
The $91.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $799 · 2021: $881 · 2022: $1,007 · 2023: $752 · 2024: $394 · 2025: $91.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,967.55 | 2019-2025 | |
| Pfizer INC. | $433.90 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $339.04 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $293.60 | 2019-2022 | |
| Lilly USA, LLC | $261.85 | 2019-2023 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.25 | 2019-2025 | |
| Novo Nordisk INC | $238.26 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $198.67 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.27 | 2022 | |
| Merck Sharp & Dohme LLC | $138.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.47 | 2019-2023 | Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $88.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.41 | 2019-2024 | |
| Exact Sciences Corporation | $67.39 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $59.48 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $52.44 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.94 | 2022 | |
| Mylan Specialty L.P. | $37.74 | 2021 | |
| Glaxosmithkline, LLC. | $36.89 | 2022-2023 | Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $32.37 | 2021 | |
| Esperion Therapeutics, INC. | $29.65 | 2020-2021 | |
| Alkermes, INC. | $21.73 | 2023 | Vivitrol |
| Xeris Pharmaceuticals, INC. | $21.43 | 2023 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $21.24 | 2024 | Ultomiris |
| Lucid Diagnostics INC. | $20.72 | 2023 | |
| Amgen INC. | $20.63 | 2023 | Repatha |
| Azurity Pharmaceuticals, INC. | $19.62 | 2023 | Edarbi |
| Ibsa Pharma INC. | $18.78 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $18.57 | 2022 | |
| Dermira, INC. | $17.66 | 2020 | |
| Biodelivery Sciences International, INC. | $17.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.79 | 2022 | |
| Genentech USA, INC. | $14.96 | 2019 | |
| Dynavax Technologies Corporation | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.